Skip to main content

Pharma/Regulatory

ICYMI: 2025 Update: EULAR Recommendations on Rheumatoid Arthritis Management

The European Alliance of Associations for Rheumatology (EULAR) has updated their rheumatoid arthritis (RA) management recommendations, notably with fewer recommendations (total of 9, down from 11 in 2022 version), by merging and removing previous recommendations.

Read Article

ICYMI: B Cells at the Brink in Sjögren Disease

A recent issue of Arthritis & Rheumatology reviews current understanding of the immunopathogenesis of Sjögren disease (SjD) and how that has influenced the quest for drug development for this most systemic autoimmune disorder.

Read Article

Generic Tofacitinib (6.26.2026)

Dr. Jack Cush reviews the news and journal articles from RheumNow.com. Updates on tofacitinib, CAR-T therapy and AI.

Read Article

2026 Guidelines for the Treatment of Axial Spondyloarthritis

ACR

New and updated clinical guidelines released today provide comprehensive, evidence-based recommendations for the management of axial spondyloarthritis (axSpA) for both adults and children. The effort includes an update to the 2019 ACR/SAA/SPARTAN treatment guidelines focusing on adults,

Read Article

Where are we with Biomarkers in Rheumatoid Arthritis?

Biomarker interest has grown considerably in the last 2 decades, owing to advances in genetics, imaging, protein, and multiomics. Despite these advances, biomarkers as the predictive holy grail of RA therapeutics and prognostication have not yet advanced beyond rheumatoid serologies and C-

Read Article

Redefining axial spondyloarthritis

An editorial in Lancet Rheumatology calls for "..reframing axSpA as a systemic, autoimmune inflammatory disease with multiorgan involvement and substantial unmet need."

The pathogenesis relies on not only HLA-B27, but also on environmental triggers, immune dysregulation, and

Read Article
Breckenridge Pharmaceutical received FDA approval for their generic version of tofacitinib on 6/4/26. 5 mg and 10 mg tablets are now available in the U.S. market, for both adult and pediatric use. Tofacitinib Tablets are manufactured in Martorelles, Spain. https://t.co/oAh0KQSFgs https://t.co/fNxEm31MAI
Dr. John Cush @RheumNow( View Tweet )

JAMA Review on Low Back Pain

A comprehensive JAMA review synthesizes current evidence on the epidemiology, pathophysiology, clinical evaluation, and treatment of nonspecific low back pain, drawing on 108 publications identified from a PubMed search (2005–2026) and the most recent guidelines from the WHO, ACP, and NICE.

Read Article
How many CAR-T’s do we need to test drive? There were 93 abstracts with CAR-T in title at #EULAR2026! Additionally, there was an excellent review (WIN) by Dr. Hector Chinoy. We know lots but have more questions. https://t.co/dGpfffaubX https://t.co/3MS1ZjQExj
Dr. John Cush @RheumNow( View Tweet )

CAR-T Cell Therapies at EULAR 2026

EurekAlert!

In an oral abstract presentation on Wednesday 3rd June, Fredrik Albach presented results for mivocabtagene autoleucel – an autologous, fully human CD19-directed CAR-T cell therapy – from Phase 1 of the prospective, open-label COMPARE trial in six patients with anti-

Read Article

Late-Breaking Studies at EULAR 2026

MedPage Today

Late-breaking abstracts presented at the European Alliance of Associations for Rheumatology's (EULAR) annual meeting, held here last week, addressed a wide range of clinical

Read Article
Long-term Cancer Risk with Targeted Therapy in SpA Dr. Antoni Chan reports on abstract OP0238 presented at EULAR 2026 in London https://t.co/f67SvKI6Vk https://t.co/fPp2H0aMoK
Dr. John Cush @RheumNow( View Tweet )
A provacative OPINION piece in The Hill asks, is "China is quietly taking control of US medicine..." Should the US & FDA facilitating, ignorning or opposing Chinas influence? Issues of transparency, manufacturing, global supply chain, outsourcing early phase RCTs, etc. https://t.co/4vveTR8UK8
Dr. John Cush @RheumNow( View Tweet )

EULAR 2026 Rheumatology RoundUp

It’s time for Rheumatology RoundUp from EULAR 2026 from London, UK. Drs. Artie Kavanaugh and Jack Cush review their choice presentations from the meeting, offering their perspectives on impact and applicability.

Read Article
SLE Pipeline of New Therapies Dr. Andrea Fava, EULAR 2026 in London. https://t.co/GwntaPwzWr https://t.co/prFnaSKuqF
Dr. John Cush @RheumNow( View Tweet )
RheumNow’s expanded coverage of the #EULAR2026 Annual Meeting is sponsored by Bristol Myers Squibb and UCB. RheumNow and its faculty independently select all coverage content.

Dr. John Cush @RheumNow( View Tweet )

All content is independently chosen and produced by the RheumNow faculty. Our expanded #EULAR2026 coverage is made possible by support from Bristol Myers Squibb and UCB.

Dr. John Cush @RheumNow( View Tweet )

RheumNow’s expanded coverage of #EULAR2026 annual meeting is sponsored by Bristol Myers Squibb and UCB. RheumNow and its faculty independently select all coverage content.

Dr. John Cush @RheumNow( View Tweet )

JAK Safety Debate Continues: Stronger VTE signal, less clear cancer signal Few topics in rheumatology have reshaped prescribing behaviour as dramatically as the safety concerns surrounding JAK inhibitors following ORAL Surveillance and the subsequent FDA and EMA warnings. https://t.co/mvTRRL7srA
Dr. John Cush @RheumNow( View Tweet )
Not all #RA pts respond equally to advanced therapy. 10-variable risk model >18k US pts: low baseline disease activity, fewer comorbidities, and no prior biologics 5x more likely to achieve remission at 1yr (34% vs 7%). RWD for precision care @RheumNow #EULAR2026 POS0257

Jiha Lee @JihaRheum( View Tweet )

Our expanded #EULAR2026 coverage is made possible by support from Bristol Myers Squibb and UCB. All content is independently chosen and produced by the RheumNow faculty.

Dr. John Cush @RheumNow( View Tweet )

Looking forward to CAR T cell therapy trials in #SSc Phase 2 and 3 studies presented at #HOT session by Pr Oliver Distler #CAR_T #EULAR2026 @RheumNow https://t.co/bmXZpF2wKg
Nelly ZIADE 🍀 @Nellziade( View Tweet )
JAK Safety Debate Continues: Stronger VTE signal, less clear cancer signal Few topics in rheumatology have reshaped prescribing behavior as dramatically as the safety concerns surrounding JAK inhibitors following ORAL Surveillance and the subsequent FDA and EMA warnings. Even https://t.co/wfQZn1hO3N
Dr. John Cush @RheumNow( View Tweet )
RheumNow’s expanded coverage of the #EULAR2026 Annual Meeting is sponsored by Bristol Myers Squibb and UCB. RheumNow and its faculty independently select all coverage content.

Dr. John Cush @RheumNow( View Tweet )

Rheumatology Shortage Cliff in Australia & USA

Australia is facing a deepening rheumatology manpower crisis with direct parallels to the situation in the United States.

Read Article
×